One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients Product Name:D-Ribose CAS No.:50-69-1 Standard:USP, EP Price(USD):0.00 International
Approvals/Standards:ISO Certificate Company:SHANGHAI PASSIONO INT'L CO., LTD.
Main Sales Markets: North America,Western Europe,Eastern Europe,Australasia,Middle East,Africa
Packaging Information: 25.0kg/drum
Sample Provided: yes
Payment Terms: T/T in advance
Product name:D-Ribose
Appearance:white powder
Shelf life:2years if properly stored
CAS no:50-69-1
Advantages:Water soluble
Delivery time:Prompt shipment
Function:
1. D-ribose can be used in Nutrition supplements and pharmaceutical intermediates.
2. D-ribose can participate in the produce process of vitamin B2, (lactoflavin), furan DNA, RNA and pyranoid and disease-resistant poison, anti-tumor, nucleoside drugs.
3. D-ribose also serves as the health care product and food additive.
Specification: D-Ribose
Appearance
White or slightly yellow crystals or crystalline powder.
Assay:
97.0-102% Min.
Loss on drying:
(In Vacuum, 3hours under 60degree C)
3.0% Max.
Residue on Ignition:
0.2% Max.
Heavy Metals
10ppm Max.
Specific Rotation:
-18.0~-22.0 degree
State of solution:
95.0% Max.
As:
2ppm Max.
Other saccharide: (Chromatographically)
not detectable
D-Ribose is our featured products and we usually ship for large batches, and if you have interest in our product,just feel free to contact me.
In addiction, we are also strong to offer OEM Service, can manufacture capsule, softgels, tablets, blended powder and so on, not only as per our own formula but as per your offered formula.
Ten years of qualification
Audited Supplier
Pharma Sources Insight January 2025
